Thursday, 06 August 2020


Orchid exits 10-year-old JV in China due to competition

15 November 2012 | News | By BioSpectrum Bureau

The deal is off - Orchid Chemicals exits manufacturing JV with North China Pharmaceutical

The deal is off - Orchid Chemicals exits manufacturing JV with North China Pharmaceutical

Chennai: Chennai-based global pharma major, Orchid Chemicals and Pharmaceuticals has exited its 50:50 manufacturing joint venture (JV) with North China Pharmaceutical (NCPC) in China.

The 50 percent stake that Orchid holds in the JV will be transferred to the partner company (NCPC) for a total cash consideration of $13.9 million (RMB 87.5 million).

Orchid had in 2002 entered into a 50:50 JV with NCPC to set up a Cephalosporin active pharmaceutical ingredient (API) manufacturing facility, located in Shijiazhuang, China.

Commenting on the development, Mr K Raghavendra Rao, CMD, Orchid, said that, "With the local Chinese players fast integrating, the operating conditions have grown quite competitive in China. Moreover, the products that the JV manufactures and markets in the local Chinese market have reached a mature stage resulting in flat growth prospects going forward. Hence, it was a prudent decision to relinquish our stake to the partner and exit the JV."


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls